

# STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (GH-133)	PRADEMAGENE ZAMIKERACEL
PRONUNCIATION	pra dem' a jeen zam" i ker' a sel
THERAPEUTIC CLAIM	Treatment of recessive dystrophic epidermolysis Bullosa (RDEB)
DESCRIPTION	

Human culture expanded genetically modified autologous keratinocytes for cell-based gene therapy. Cells are isolated from skin of the patient, expanded and transduced with replication incompetent and non-self-inactivating Moloney murine leukemia virus (MMLV) derived retroviral vector encoding the functional collagen type VII alpha 1 chain (COL7A1) under the control of the mouse phosphoglycerol kinase-1 (mPGK-1) promoter genetically modified cell (functional collagen synthesis promotion)

## SCHEMATIC MAP



TRADEMARK	None as yet
SPONSOR	Abeona Therapeutics, Inc.
CODE DESIGNATION	EB-101
CAS REGISTRY NUMBER	2088280-15-1
UNII	4UU2O40RHU
WHO NUMBER	10827

SCS